Thinking of or on the IVF journey? The following may have some relevance in your decision process.
In the past two decades there has been a significant rise in IVF clinics worldwide offering costly testing of embryos to make sure they have the right number of chromosomes.
Genetic testing for aneuploidy (PGT-A) has become a routine add-on for in vitro fertilization (IVF) to determine whether human embryos are to be clinically utilized or disposed of.
The theory is this will improve the chance of a baby by ensuring only chromosomally normal embryos are transferred.
A recently published study shows pre-implantation genetic testing for aneuploidy (PGT-A), as the test is called, does not increase the odds of having a baby, at least not in women under the age of 38.
"PGT-A was never clinically validated in its ability to define a human embryo as chromosomal normal, mosaic, or aneuploid, nor certified by a regulatory body, or an authoritative professional organisation".
Because of a high false-positive rate, PGT-A, actually reduces live IVF birth chances for many patients. Furthermore, in recent studies the PGT-A hypothesis was demonstrated to be mistaken for biological, mathematical and technical reasons. PGT-A, therefore, should clinically only be offered within experimental study frameworks.
Resources:
Click on the logo for the detail
